Contineum Therapeutics (CTNM) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic focus and clinical approach

• Emphasizes early clinical de-risking through validated targets, dose-receptor studies, and cognitive safety assessments.

• Prioritizes neuroscience, inflammation, and immunology, with two clinical-stage assets targeting four diseases.

• Selective targeting of muscarinic and LPA1 receptors aims to avoid cognitive liabilities and maximize efficacy.

• All assets developed in-house, with strong patent protection through 2040–2042.

• IPO completed in April 2024, raising $110 million and providing cash runway through 2027.

Pipeline highlights and clinical progress

• PIPE-307: First-in-class M1 receptor inhibitor in phase II for relapsing-remitting MS, with a depression study launching with J&J.

• PIPE-791: Brain-penetrant LPA1 inhibitor advancing in progressive MS and IPF, with phase 1b PET study and chronic tox to complete by early 2025.

• CTX-343: Peripherally restricted LPA1 inhibitor, IND filing and healthy volunteer study planned for 2025.

• J&J partnership for PIPE-307 includes $1.1 billion in milestones, $50 million upfront, and co-development options.

• Two phase II proof-of-concept studies for PIPE-791 in IPF and progressive MS planned for 2025.

Market opportunity and competitive landscape

• IPF represents a large unmet need, with current drugs showing poor tolerability and efficacy; 30–50% of patients refuse or discontinue treatment.

• LPA1 antagonism validated by BMS and Amgen, but prior compounds had safety or dosing issues.

• PIPE-791 aims for 90%+ receptor coverage with QD dosing, potentially improving outcomes and safety.

• Current IPF drugs generate significant sales despite limitations, highlighting market potential.

• PIPE-791’s slow dissociation rate enables sustained exposure and supports once-daily dosing.